The U.S. Food and Drug Administration has warned Novo Nordisk over a consumer ad for its blockbuster diabetes drug, Ozempic, saying the commercial makes false and misleading claims about the drug’s benefits.
It is the second time in less than a month that the FDA has warned the Danish drugmaker about its misleading ads.
The warning comes amid a broader FDA crackdown on misleading drug advertising, following U.S. President Donald Trump’s order for tighter oversight of how companies promote prescription drugs.
In a letter dated February 26, the health regulator said the online ad misrepresented Ozempic’s approved uses and implied that the drug was superior to other GLP‑1 medicines for type 2 diabetes….